Novo Holdings Kinnate Biopharma Inc. Transaction History

Novo Holdings

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $1.42 Million - $2.49 Million	191,471 Added 30.67%	815,707 $10.3 Million
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $549,664 - $1.28 Million	71,108 Added 12.86%	624,236 $7.03 Million
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $900,900 - $1.39 Million	54,600 Added 10.95%	553,128 $9.8 Million
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $3.54 Million - $4.94 Million	198,528 Added 66.18%	498,528 $11.5 Million
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $10.9 Million - $13.6 Million	300,000 New	300,000 $11.9 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

Stay updated on Novo Holdings with notifications on news.